- Home
- GXAI vs INTS Comparison
GXAI vs INTS Comparison
Compare GXAI & INTS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GXAI
- INTS
- Stock Information
- Founded
- GXAI 2021
- INTS 2012
- Country
- GXAI United States
- INTS United States
- Employees
- GXAI N/A
- INTS N/A
- Industry
- GXAI
- INTS Biotechnology: Pharmaceutical Preparations
- Sector
- GXAI
- INTS Health Care
- Exchange
- GXAI Nasdaq
- INTS Nasdaq
- Market Cap
- GXAI 7.3M
- INTS 8.7M
- IPO Year
- GXAI 2023
- INTS 2023
- Fundamental
- Price
- GXAI $1.41
- INTS $0.46
- Analyst Decision
- GXAI
- INTS Strong Buy
- Analyst Count
- GXAI 0
- INTS 3
- Target Price
- GXAI N/A
- INTS $8.50
- AVG Volume (30 Days)
- GXAI 136.7K
- INTS 1.3M
- Earning Date
- GXAI 06-13-2025
- INTS 05-13-2025
- Dividend Yield
- GXAI N/A
- INTS N/A
- EPS Growth
- GXAI N/A
- INTS N/A
- EPS
- GXAI N/A
- INTS N/A
- Revenue
- GXAI $27,740.00
- INTS N/A
- Revenue This Year
- GXAI N/A
- INTS N/A
- Revenue Next Year
- GXAI N/A
- INTS N/A
- P/E Ratio
- GXAI N/A
- INTS N/A
- Revenue Growth
- GXAI 9987.27
- INTS N/A
- 52 Week Low
- GXAI $1.00
- INTS $0.29
- 52 Week High
- GXAI $7.50
- INTS $5.10
- Technical
- Relative Strength Index (RSI)
- GXAI 57.83
- INTS 38.44
- Support Level
- GXAI $1.37
- INTS $0.29
- Resistance Level
- GXAI $1.49
- INTS $0.63
- Average True Range (ATR)
- GXAI 0.10
- INTS 0.09
- MACD
- GXAI 0.00
- INTS 0.06
- Stochastic Oscillator
- GXAI 71.19
- INTS 50.88
About GXAI Gaxos.ai Inc.
Gaxos.AI Inc is revolutionizing the way humans interact with artificial intelligence. The company offers applications related to mental and physical well-being, coaching, and gaming. The group is committed to tackling contemporary challenges such as how to live healthier and how to live longer. In addition to offering human-centered solutions, the company uses empathetic and AI technologies.
About INTS Intensity Therapeutics Inc. Common stock
Intensity Therapeutics Inc is a clinical-stage biotechnology company pioneering a new immune-based approach to treat solid tumor cancers. The company leverages its DfuseRxtechnology platform to create new, proprietary drug formulations that, following direct injection, rapidly disperse throughout a tumor and diffuse therapeutic agents into cancer cells. Intensity's product candidates have the potential to induce an adaptive systemic immune response that not only attacks the injected tumor, but also non-injected tumors. Their pipeline is focused on realizing the full potential of INT230-6 in metastatic and local disease settings to help cancer patients with unmet medical need.